Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a challenge and is associated with poor long-term survival. Chimeric antigen recep...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of hematology and oncology Ročník 10; číslo 1; s. 35 - 8
Hlavní autoři: Liu, Jun, Zhong, Jiang F., Zhang, Xi, Zhang, Cheng
Médium: Journal Article
Jazyk:angličtina
Vydáno: London BioMed Central 31.01.2017
Springer Nature B.V
BMC
Témata:
Allogeneic hematopoietic stem cell transplantation
Antigens
Antigens, CD19 - immunology
B-Lymphocytes - pathology
Cancer Research
CAR-T cells
Chemotherapy
Clinical Trials as Topic
Graft versus host disease
Hematologic Neoplasms - pathology
Hematologic Neoplasms - therapy
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Humans
Immunotherapy, Adoptive - methods
Leukemia
Lymphocytes
Lymphoid malignancies
Lymphoma
Medicine
Medicine & Public Health
Oncology
Patients
Recurrence
Remission (Medicine)
Review
Stem cell transplantation
T-Lymphocytes - transplantation
Time Factors
Lymphoid malignancies
CAR-T cells
Allogeneic hematopoietic stem cell transplantation
ISSN:1756-8722, 1756-8722
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a challenge and is associated with poor long-term survival. Chimeric antigen receptor redirected T cells (CAR-T cells) can lead to disease remission in patients with relapsed/refractory hematological malignancies. However, the therapeutic window for infusion of CAR-T cells post allo-HSCT and its efficacy are debatable. Main body In this review, we first discuss the use of CAR-T cells for relapsed cases after allo-HSCT. We then review the toxicities and the occurrence of graft-versus-host disease in relapsed patients who received CAR-T cells post allo-HSCT. Finally, we review clinical trial registrations and the therapeutic time window for infusion of CAR-T cells post allo-HSCT. Conclusions The treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications. However, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-017-0405-3